Topic: infectious disease
GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.
A new study showed Ocrevus could reduce patients' immune responses to vaccines against tetanus, seasonal flu and pneumococcus.
With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.
The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
Here is some other vaccine news of note for the week.
A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.
The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.